

1 **Interactions between sleep disturbances and Alzheimer’s**
2 **disease on brain function: a preliminary study combining**
3 **the static and dynamic functional MRI**

4 Kaicheng Li^{1†}, Xiao Luo^{1†}, Qingze Zeng¹, Yefan Jiaerken¹, Shuyue Wang¹, Xiaopei Xu¹,
5 Xiaojun Xu¹, Jingjing Xu¹, Chao Wang¹, Jiong Zhou², Peiyu Huang^{*1}, Minming Zhang^{*1}

6
7 ¹Department of Radiology, 2nd Affiliated Hospital of Zhejiang University School of
8 Medicine, China

9 ²Department of Neurology, 2nd Affiliated Hospital of Zhejiang University School of
10 Medicine, China

11
12 Corresponding to:

13 *Prof. Minming Zhang, MD, PhD

14 Department of Radiology, The 2nd Affiliated Hospital of Zhejiang University, School of
15 Medicine, No.88 Jie-fang Road, Shang-cheng District, Hangzhou, China, 310009; Phone:
16 86-0571-87315255; Fax: 86-0571-87315255; Email address: zhangminming@zju.edu.cn

17 *Prof. Peiyu Huang, PhD

18 Department of Radiology, The 2nd Affiliated Hospital of Zhejiang University, School of
19 Medicine, No.88 Jie-fang Road, Shang-cheng District, Hangzhou, China, 310009; Phone:
20 86-0571-87315255; Fax: 86-0571-87315255; Email address: hpyzju@foxmail.com

21
22
23 **Supplementary Material 1. Flow chart of subjects inclusion**


24 We identified 741 subjects who had sleep-related records in the medical history or
25 night-time behavioral disturbance assessed by Neuropsychiatric Inventory (NPI) ¹ or a brief
26 questionnaire form of NPI (NPI-Q) ² from ADNI GO, ADNI 2 and ADNI 3 database before
27 2018 September. After careful screening, 234 subjects were excluded due to rest-state

28 functional MRI (rsfMRI) data missing; 56 subjects were excluded due to inconformity
29 between sleep complaint and rsfMRI time; 60 subjects were excluded due to different rsfMRI
30 scan parameters or bad image quality; 58 subjects were excluded due to abnormal cognitive
31 performance (Notably, in some samples, we selected data from the follow-up time points to
32 ensure the time-correspondence of different image data, which may have different diagnosis
33 from the baseline). Finally, we included 333 subjects undergone rsfMRI, structural scan, and
34 comprehensive neuropsychological assessments. According to their cognition state, these
35 subjects can be further grouped into normal control (NC), subjects with mild cognitive
36 impairment (MCI) and Alzheimer's disease (AD) patients (Figure S1).

37 The inclusion criteria for NC as followed: (a) Mini-Mental State Examination (MMSE)
38 between 24 and 30 (inclusive); (b) the clinical dementia rating (CDR) score of 0; (c) the
39 normal Wechsler Memory Scale Logical Memory (WMS-LM), delay recall performance (in
40 detail: ≥ 9 for subjects with 16 or more years of education; ≥ 5 for subjects with 8 – 15 years
41 of education; and ≥ 3 for 0 – 7 years of education); (d) non-clinical depression (geriatric
42 depression scale-15, GDS-15 score < 6)³; and (e) non-demented. The inclusion criteria for
43 MCI subjects are: having (a) subjective memory complaints, either self-reported, reported by
44 a study partner, or reported by a clinician; (b) decreased WMS-LM delayed recall
45 performance; (c) CDR score of 0.5; (d) MMSE score between 24 and 30 (inclusive); and (e)
46 general cognitive and functional performance sufficiently preserved such that a diagnosis of
47 dementia could not be made by the site physician at the time of screening⁴. Regarding AD,
48 the inclusion criteria were: (a) MMSE score of ≤ 26 ; (b) CDR ≥ 0.5 , and (c) meeting the
49 NINCDS/ADRDA criteria for probable AD⁵.

50 We excluded subjects with the following manifestations: (a) significant medical,
 51 neurological, and psychiatric illness; (b) obvious head trauma history; (c) use of
 52 non-AD-related medication known to influence cerebral function; (d) clinical depression; (e)
 53 alcohol or drug abuse.

54 Figure S1. Flow chart of subjects inclusion



55
 56 **Abbreviation:** rsfMRI: rest-state functional MRI; GDS: geriatric depression scale; NC: normal control; MCI:
 57 mild cognitive impairment; AD: Alzheimer's disease; NS: normal sleeper; PS: poor sleeper; NPI:
 58 Neuropsychiatric Inventory; NPI-Q: a brief questionnaire form of NPI.

59

60 Supplementary Material 2

61 We defined sleep quality using medical history (keywords: “insomnia”, “sleep problem”,
 62 and “sleep apnea”) and night-time behaviour scale in Neuropsychiatric Inventory (NPI) or a
 63 brief questionnaire form of NPI (NPI-Q), as previously described ^{2,6-8}. Specifically, we
 64 defined subjects with sleep disturbance (including sleep problems recorded in the medical
 65 history or abnormal NPI/NPI-Q) as the poor sleeper; by contrast, subjects with both normal
 66 medical history and NPI/NPI-Q were defined as the normal sleeper.

67 To be specific, NPI or NPI-Q^{1,2} is a caregiver-based tool which assesses the possible
68 presence of neuropsychiatric symptoms in dementia cases, including night-time behavioural
69 disturbances. For detail, NPI/NPI-Q consists of 12 items (including delusions, hallucinations,
70 agitation/aggression, dysphoria/depression, anxiety, euphoria/elation, apathy/indifference,
71 disinhibition, irritability/lability, aberrant motor behaviors, night-time behavioral disturbances
72 and appetite/eating disturbances) that the caregiver rates on a scale from 1 to 4 as to whether
73 there has been no change or some degree of change and a severity range from 1 to 3 in each of
74 neuropsychiatric symptoms.


75 Thereinto, the 9th item of NPI assesses the night-time behavior, which asked like “Does
76 the patient awaken you during the night, rise too early in the morning, or take excessive naps
77 during the day?” This item can reflect decreased nighttime sleep and increased daytime sleep,
78 which both belong to the sleep disturbance and might impair cognition⁹. A sleep disturbance
79 symptom was considered to be present if a caregiver reported the symptom (the scale score of
80 the 9th item ≥ 1). Previous studies have used NPI to measure sleep characteristics in MCI or
81 AD and proved its validity¹⁰⁻¹².

82

83 **Supplementary Material 3: Design matrix of the full factorial model**

84 The interactions between sleep disturbance and disease severity on brain function (both
85 sALFF and dALFF in a whole-brain voxel-wise way) were assessed with a 3×2 full factorial
86 design, with groups (NC, MCI, and AD) and sleep state (NS and PS) as between-participant
87 factors. Age, gender, education and FD were employed as covariates (Figure S2, S3).
88 Figure S2. Design matrix of the full factorial model

Statistical analysis: Design



Design description...

Design : Full factorial
Global calculation : omit
Grand mean scaling : <no grand Mean scaling>
Global normalisation : <no global normalisation>
Parameters : 6 condition, +4 covariate, +0 block, +0 nuisance
 10 total, leaving 10 degrees of freedom
 leaving 323 degrees of freedom from 333 images

89

90

91

92 **Supplementary Material 4: The main effect and interaction effect on neuropsychological**
 93 **performance**

94 Table S1. The demographic and cognitive information of NC

Demographic Characteristics	NC		P value	T/X ²
	NS (N=123)	PS (N=69)		
Age,y, mean (SD)	74.02 ± 7.13	74.77 ± 6.57	0.47	-0.72
Female, n (%)	70/123	46/69	0.22	1.76
Education,y, mean (SD)	16.52 ± 2.16	16.39 ± 2.43	0.70	0.38

<i>Neuropsychiatric Scores</i>				
GDS	0.65±0.98	1.20±1.15	0.001*	-3.54
<i>General mental status</i>				
MMSE	29.20±1.06	29.12±1.04	0.59	0.55
CDR global	0.00±0.00	0.00±0.00	0.46	0.75
CDR sum	0.01±0.00	0.00±0.00	0.46	0.75
<i>Memory function</i>				
WMS-LM immediate	14.39±3.54	15.13±3.17	0.15	-1.45
WMS-LM delay	13.38±3.73	14.03±3.46	0.24	-1.18
AVLT sum of trials 1–5	13.06±2.11	13.36±2.29	0.36	-0.93
AVLT 30min	7.77±4.23	8.65±3.54	0.14	-1.47
<i>Attention</i>				
Log-transformed TMT-A	1.49±0.13	1.46±0.11	0.14	1.49
<i>Decision-making function</i>				
Log-transformed TMT-B	1.86±0.20	1.83±0.14	0.42	0.81
<i>Language</i>				
Category verbal fluency	21.57±5.30	21.97±4.70	0.60	-0.53
<i>Visuospatial processing</i>				
CDT	4.75±0.45	4.74±0.53	0.84	0.21

95 Data are presented as means ± standard deviations.

96 Abbreviation: NC: normal control; NS: normal sleeper; PS: poor sleeper; GDS: Geriatric Depression Scale;

97 MMSE, Mini-Mental State Examination; CDR: Clinical Dementia Rating; WMS-LM, Wechsler Memory Scale

98 Logical Memory; AVLT, Auditory Verbal Learning Test; TMT, Trail-Making Test; CDT, Clock Drawing Test.

99 *p<0.05, significant difference between groups

100

101 Table S2. The demographic and cognitive information of MCI

Demographic characteristics	MCI		P value	T/X ²
	NS (N=39)	PS (N=72)		
Age,y, mean (SD)	73.41±8.07	73.78±6.72	0.80	-0.25
Female, n (%)	19/39	30/72	0.52	1.30
Education,y, mean (SD)	16.23±3.17	16.10±2.67	0.81	0.24
<i>Neuropsychiatric Scores</i>				
GDS	1.10±1.27	1.94±1.76	0.01*	-2.64
<i>General mental status</i>				
MMSE	27.77±2.64	27.03±3.89	0.29	1.07
CDR global	0.42±0.24	0.49±0.32	0.24	-1.19
CDR sum	1.21±1.45	1.53±2.07	0.39	-1.29
<i>Memory function</i>				
WMS-LM immediate	9.74±4.60	10.43±4.39	0.46	-0.75
WMS-LM delay	7.71±5.59	8.10±4.98	0.72	-0.36
AVLT sum of trials 1–5	11.11±3.63	10.42±3.79	0.37	0.91
AVLT 30min	4.82±3.97	4.76±5.57	0.95	0.06
<i>Attention</i>				

Log-transformed TMT-A	1.54±0.15	1.56±0.18	0.50	-0.67
<i>Decision-making function</i>				
Log-transformed TMT-B	1.97±0.22	1.96±0.24	0.79	0.27
<i>Language</i>				
Category verbal fluency	18.44±5.50	17.69±6.14	0.53	0.63
<i>Visuospatial processing</i>				
CDT	4.32±1.02	4.39±1.00	0.72	-0.36

102 Data are presented as means ± standard deviations.

103 Abbreviation: MCI: mild cognitive impairment; NS: normal sleeper; PS: poor sleeper; GDS: Geriatric
104 Depression Scale; MMSE, Mini-Mental State Examination; CDR: Clinical Dementia Rating; WMS-LM,
105 Wechsler Memory Scale Logical Memory; AVLT, Auditory Verbal Learning Test; TMT, Trail-Making Test; CDT,
106 Clock Drawing Test.

107 *p<0.05, significant difference between groups

108

109 Table S3. The demographic and cognitive information of AD

Demographic characteristics	AD		P value	T/X²
	NS (N=14)	PS (N=16)		
Age,y, mean (SD)	70.76±8.24	74.66±8.50	0.21	-1.27
Female, n(%)	5/14	9/16	0.30	1.27
Education,y, mean (SD)	15.57±2.77	16.38±2.58	0.42	-0.82
<i>Neuropsychiatric Scores</i>				
GDS	1.86±0.95	1.75±1.57	0.83	0.22
<i>General mental status</i>				

MMSE	22.93 ± 2.67	20.81 ± 4.42	0.13	1.56
CDR global	0.75 ± 0.26	1.00 ± 0.55	0.13	-1.56
CDR sum	3.79 ± 1.12	5.50 ± 3.46	0.09	-1.77
<i>Memory function</i>				
WMS-LM immediate	4.25 ± 2.99	4.27 ± 2.99	0.99	-0.02
WMS-LM delay	1.75 ± 2.22	1.07 ± 1.83	0.39	0.88
AVLT sum of trials 1–5	5.13 ± 3.36	4.13 ± 3.67	0.53	0.65
AVLT 30min	0.50 ± 0.93	0.31 ± 1.25	0.71	0.37
<i>Attention</i>				
Log-transformed TMT-A	1.76 ± 0.24	1.86 ± 0.20	0.26	-1.15
<i>Decision-making function</i>				
Log-transformed TMT-B	2.10 ± 0.18	2.35 ± 0.17	0.02*	-2.57
<i>Language</i>				
Category verbal fluency	10.50 ± 4.87	12.44 ± 5.81	0.43	-0.81
<i>Visuospatial processing</i>				
CDT	3.14 ± 2.12	3.25 ± 1.57	0.89	-0.14

110 Data are presented as means ± standard deviations.

111 Abbreviation: AD: Alzheimer's disease; NS: normal sleeper; PS: poor sleeper; GDS: Geriatric Depression Scale;

112 MMSE, Mini-Mental State Examination; CDR: Clinical Dementia Rating; WMS-LM, Wechsler Memory Scale

113 Logical Memory; AVLT, Auditory Verbal Learning Test; TMT, Trail-Making Test; CDT, Clock Drawing Test.

114 *p<0.05, significant difference between groups

115

116 Table S4. The main effect and interaction effect on neuropsychological performance

Demographic	NC	MCI	AD			P-value
--------------------	-----------	------------	-----------	--	--	----------------

characteristics	NS (N=123)	PS (N=69)	NS (N=39)	PS (N=72)	NS (N=14)	PS (N=16)	P-value Sleep quality	P-value Disease severity	Sleep × Disease interacti on
MMSE	29.20±1.06	29.12±1.04	27.77±2.64	27.03±3.89	22.93±2.67	20.81±4.42	0.01	<0.001	0.10
WMS-LM immediate	14.39±3.54	15.13±3.17	9.74±4.60	10.43±4.39	4.25±2.99	4.27±2.99	0.48	<0.001	0.75
WMS-LM delay	13.38±3.73	14.03±3.46	7.71±5.59	8.10±4.98	1.75±2.22	1.07±1.83	0.80	<0.001	0.65
AVLT sum of trials 1–5	13.06±2.11	13.36±2.29	11.11±3.63	10.42±3.79	5.13±3.36	4.13±3.67	0.41	<0.001	0.31
AVLT 30min	7.77±4.23	8.65±3.54	4.82±3.97	4.76±5.57	0.50±0.93	0.31±1.25	0.96	<0.001	0.55
Log-transformed TMT-A	1.49±0.13	1.46±0.11	1.54±0.15	1.56±0.18	1.76±0.24	1.86±0.20	0.14	<0.001	0.06
Log-transformed TMT-B	1.86±0.20	1.83±0.14	1.97±0.22	1.96±0.24	2.10±0.18	2.35±0.17	0.12	<0.001	0.07
Category verbal fluency	21.57±5.30	21.97±4.70	18.44±5.50	17.69±6.14	10.50±4.87	12.44±5.81	0.42	<0.001	0.44
CDT	4.75±0.45	4.74±0.53	4.32±1.02	4.39±1.00	3.14±2.12	3.25±1.57	0.87	<0.001	0.87

117 Data are presented as means ± standard deviations.

118 Abbreviation: AD: Alzheimer's disease; NS: normal sleeper; PS: poor sleeper; GDS: Geriatric Depression Scale;

119 MMSE, Mini-Mental State Examination WMS-LM, Wechsler Memory Scale Logical Memory; AVLT, Auditory

120 Verbal Learning Test; TMT, Trail-Making Test; CDT, Clock Drawing Test.

121

122 **Supplementary Material 5: The main effects of disease and sleep**

123 **The main effect of disease**

124 As for the static amplitude of low-frequency fluctuation (sALFF) analysis, the main

125 effect of disease was widely observed, especially in the temporal region (Table S5, Figure S3).

126 As for the dynamic ALFF (dALFF) variance analysis, the main effect of disease was widely
 127 observed in the cerebellum, temporal region and parietal region (Table S5, Figure S4). The
 128 findings are in line with previous studies on the anatomical location of AD-related changes.

129 Table S5. The main effect of disease


Neuroimaging Metrics	Cluster/peak regions	MNI coordinates			Extent	Max T
		X	Y	Z		
sALFF	Cerebelum_9_R	9	-42	-51	14	11.73
	Cerebelum_9_L	-12	-45	-51	14	11.40
	Cerebelum_8_R	36	-54	-45	11	12.16
	Temporal_Pole_Sup_R	36	12	-30	10	9.15
	Temporal_Pole_Sup_L	-36	9	-27	62	15.64
	Amygdala_R	24	0	-21	14	11.33
	Temporal_Inf_L	-42	-36	-18	17	18.27
	Temporal_Inf_R	48	-27	-27	12	11.98
	Fusiform_L	-33	-54	-6	19	17.29
	Insula_L	-33	18	12	10	12.74
	SupraMarginal_R	60	-45	24	10	10.17
	Calcarine_R	18	-57	6	11	13.21
	Frontal_Mid_R	42	6	39	14	10.54
Temporal_Sup_R	48	-24	9	11	10.84	
	Cerebelum_8_L	-30	-60	-54	14	10.40
	Cerebelum_7b_L	-36	-48	-42	18	15.79

dALFF variance	Cerebelum_Crus1_L	-42	-60	-27	27	12.00
	Cerebelum_6_R	36	-48	-27	71	15.93
	Vermis_4_5	6	-51	3	17	14.03
	Fusiform_L	-36	-15	-30	23	13.54
	Temporal_Inf_L	-42	-39	-18	80	16.92
	Temporal_Inf_R	50	-9	-36	31	13.06
	Temporal_Pole_Sup_L	-36	9	-27	155	18.35
	Temporal_Pole_Sup_R	36	18	-30	20	15.27
	Frontal_Mid_L	-30	39	45	33	12.16
	Frontal_Mid_L	-39	15	54	24	14.27
	Angular_R	42	-57	24	18	13.44
	Parietal_Sup_L	-15	-66	48	20	13.71
	Parietal_Inf_L	-24	-54	54	14	14.56

130 Abbreviation: sALFF, static amplitude of low-frequency fluctuation; dALFF, dynamic amplitude of low-frequency
131 fluctuation.

132


133 Figure S3. The main effect of disease on sALFF



134

135 Abbreviation: sALFF, static amplitude of low-frequency fluctuation

136 Figure S4. The main effect of disease on dALFF variance



137

138 Abbreviation: dALFF, dynamic amplitude of low-frequency fluctuation.

139

140 **The main effect of sleep**

141 As for the sALFF analysis, the main effect of sleep on the ALFF was primarily located in
 142 IPG, cerebellum, and motor-related region (Table S6, Figure S5). As for the dALFF variance
 143 analysis, the main effect of sleep quality on the ALFF was primarily located in the cerebellum,
 144 gyrus rectus and superior frontal gyrus (Table S6, Figure S6). The findings are in line with
 145 previous studies reporting sleep relates with the motor memory consolidation and emotional
 146 memory during sleep. This study suggested it widely involved in networks including
 147 hippocampo-striato-thalamo-cortical networks ¹³, hippocampus-amygdala system ¹⁴ and
 148 hippocampal-cortical communication ¹⁵. These findings are partially similar to previous
 149 studies which reported that poor sleep quality was associated with reduced GM volume in the
 150 frontal cortex, temporal, parietal regions, postcentral gyrus, precuneus and insula ¹⁶⁻¹⁸.

151 Table S6. The main effect of sleep


Neuroimaging Metrics	Cluster/peak regions	MNI coordinates			Extent	Max T
		X	Y	Z		
sALFF	Cerebelum_Crus1_R	45	-51	-36	8	17.80
	Temporal_Inf_R	45	-54	-9	9	21.66
	Occipital_Sup_R	24	-78	24	10	21.84
	Precuneus_L	-18	-63	36	11	17.55
	Parietal_Inf_L	-54	-30	42	8	18.51
	Parietal_Inf_R	54	-48	39	33	26.40
	Postcentral_L	-51	-6	42	8	16.09

	Postcentral_R	30	-42	54	9	17.15
	Supp_Motor_Area_R	12	15	51	9	16.31
	Supp_Motor_Area_L	-6	9	57	7	15.63
dALFF variance	Cerebellum_8_R	30	-42	-51	12	18.77
	Cerebellum_Crus2_R	45	-69	-45	16	18.21
	Cerebellum_Crus1_R	45	-51	-36	8	16.24
	Cerebellum_3_R	9	-36	-18	9	13.80
	Frontal_Sup_Orb_L	-15	27	-21	9	17.84
	Rectus_R	3	27	-15	34	21.88

152 Abbreviation: sALFF, static amplitude of low-frequency fluctuation; dALFF, dynamic amplitude of low-frequency
 153 fluctuation.

154

155 Figure S5. The main effect of sleep on sALFF




156

157 Abbreviation: sALFF, static amplitude of low-frequency fluctuation

158

159 Figure S6. The main effect of sleep on dALFF variance



160

161 Abbreviation: dALFF, dynamic amplitude of low-frequency fluctuation.


162

163 **Supplementary Material 6: The interaction effects between sleep quality and disease**
164 **severity in every ROI with the window size of 14 TR**

165 Here, we found the altered dALFF variance in superior temporal gyrus, hippocampus,
166 gyrus rectus, supramarginal gyrus, insula, thalamus, and cerebellum. In subjects with poor
167 sleep, we found an increased trend of dALFF variance along AD spectrum which suggested
168 the decreased brain activity stability, especially involving the MCI to AD stage. As for the
169 subjects with normal sleep, we found initially increased and then decreased dALFF variance
170 along AD spectrum which may reflect the compensatory enhancement in the MCI stage and

171 decompensation in the AD stage (Figure S7).

172 Figure S7.



173

174 Abbreviation: STG, superior temporal gyrus; HP, hippocampus.

175

176 **Supplementary Material 7: The interaction effects between sleep quality and disease**
 177 **severity with other window sizes**

178 To test the reliability of the dALFF results, we also examined the results with window
 179 sizes of 20, 26, 33 TR (Table S7). The results are similar with the results under widow size of
 180 14 TR, involving the cerebellum, temporal region, and insula.

181 Table S7. The interaction effects between sleep quality and disease severity with other
 182 window sizes

Window sizes	Cluster/peak regions	MNI coordinates			Extent	Max T
		X	Y	Z		
	Cerebelum_8_R	27	-48	-48	9	9.60
	Cerebelum_Crus1_R	51	-57	-33	7	8.45
	Temporal_Pole_Sup_L	-36	15	-30	11	12.54

20 TR	Temporal_Inf_L	-39	-33	-15	7	8.72
	Frontal_Inf_Orb_L	-27	21	-24	7	12.46
	Rectus_R	6	27	-18	13	10.25
	Insula_L	-39	-3	3	7	9.73
	Insula_R	39	-3	6	8	10.73
26 TR	Cerebellum_8_R	27	-45	-48	11	10.16
	Cerebellum_Crus1_R	51	-57	-33	8	8.59
	Temporal_Pole_Sup_L	-36	15	-30	7	10.81
	Rectus_R	6	27	-18	9	10.06
	Insula_R	39	-9	9	9	11.99
33 TR	Cerebellum_8_R	27	-45	-48	13	10.49
	Temporal_Inf_L	-39	0	-39	6	10.64
	Temporal_Pole_Sup_L	-36	15	-30	6	10.01
	Hippocampus_L	-36	-15	-15	6	8.89
	Rectus_R	6	27	-18	9	9.65
	Insula_R	39	-9	9	8	11.73

183

184 **Supplementary Material 8: The interaction effects between sleep quality and disease**
185 **severity by adding GDS as a covariate**

186 Previous study reported that sleep disturbance and depressive symptoms might affect
187 each other. To be specific, whether sleep disturbance may represent early symptoms of AD,
188 or induce cognitive impairment through alterations in sleep-dependent memory


189 consolidation or through an increase of depressive symptoms is still under debate ^{19,20}. Here,
190 to explore the possible effect of GDS, we repeated our full factorial analysis by adding GDS
191 as a covariate. To be specific, a 3 × 2 full factorial design, with groups (NC, MCI, and AD)
192 and sleep state (NS and PS) as between-participant factors was performed to explore the
193 interactions between sleep disturbance and disease severity on brain function (dALFF in a
194 whole-brain voxel-wise way). GDS, age, gender, education and FD were employed as
195 covariates. Then, F test was performed by setting the threshold at P<0.001 at a voxel level,
196 with P<0.05 at the cluster level, corrected for multiple comparisons using the Gaussian
197 random field (GRF) method. Results remained largely unchanged (Figure S9, Table S8),
198 suggesting that GDS has no significant effect on the results.
199 Table S8. The difference of dALFF variance of 6 groups by adding GDS as a covariate

Neuroimaging Metrics	Cluster/peak regions	MNI coordinates			Extent	Max T
		X	Y	Z		
dALFF variance	Cerebelum_Crus1_R	48	-57	-33	8	8.01
	Cerebelum_8_R	24	-45	-45	10	9.31
	Insula_R	39	-3	6	9	10.41
	Insula_L	-39	-3	3	9	10.45
	Temporal_Pole_Sup_L	-36	15	-30	13	14.32
	Hippocampal_R	21	-9	-21	9	10.31
	Rectus_R	6	27	-18	16	10.24
	SupraMarginal_R	57	-42	27	9	10.02

200 Abbreviation: dALFF, dynamic amplitude of low-frequency fluctuation; GDS, Geriatric

201 Depression Scale

202 Figure S8. The difference of dALFF variance of 6 groups by adding GDS as a covariate



203

204 Abbreviation: GDS, Geriatric Depression Scale; dALFF, dynamic amplitude of low-frequency
205 fluctuation

206

207 Reference

- 208 1 Cummings, J. L. *et al.* The Neuropsychiatric Inventory: comprehensive assessment of psychopathology
209 in dementia. *Neurology* **44**, 2308-2314 (1994).
- 210 2 Kaufer, D. I. *et al.* Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. *J*
211 *Neuropsychiatry Clin Neurosci* **12**, 233-239, doi:10.1176/jnp.12.2.233 (2000).
- 212 3 Sheikh JI, Y. J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version.
213 *In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: The*
214 *Haworth Press; , 165–173 (1986).*
- 215 4 Bondi MW, E. E., Jak AJ, Clark LR, DelanoWood L, McDonald CR, Nation DA, Libon DJ, Au R, Galasko D,
216 Salmon DP. Neuropsychological criteria for mild cognitive impairment improves diagnostic precision,
217 biomarker associations, and progression rates. *J Alzheimers Dis* **42**, 275-289 (2014).
- 218 5 G. McKhann, D. D., M. Folstein, R. Katzman, D. Price, E.M. Stadlan. Clinical diagnosis of Alzheimer's
219 disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and
220 Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-944 (1984).
- 221 6 Mecca, A. P. *et al.* Sleep Disturbance and the Risk of Cognitive Decline or Clinical Conversion in the
222 ADNI Cohort. *Dement Geriatr Cogn Disord* **45**, 232-242, doi:10.1159/000488671 (2018).

- 223 7 Moran, M. *et al.* Sleep disturbance in mild to moderate Alzheimer's disease. *Sleep Med* **6**, 347-352,
224 doi:10.1016/j.sleep.2004.12.005 (2005).
- 225 8 Benedict, C. *et al.* Self-reported sleep disturbance is associated with Alzheimer's disease risk in men.
226 *Alzheimers Dement* **11**, 1090-1097, doi:10.1016/j.jalz.2014.08.104 (2015).
- 227 9 Shi L, C. S., Ma MY, Bao YP, Han Y, Wang YM, Shi J, Vitiello MV, Lu L. Sleep disturbances increase the risk
228 of dementia: A systematic review and meta-analysis. *Sleep Med Rev* **40**, 4-16 (2018).
- 229 10 Liguori C, M. N., Nuccetelli M, Izzi F, Bernardini S, Placidi F. Cerebrospinal Fluid Orexin Levels and
230 Nocturnal Sleep Disruption in Alzheimer's Disease Patients Showing Neuropsychiatric Symptoms. *J*
231 *Alzheimers Dis* **66**, 993-999 (2018).
- 232 11 Terum TM, T. I., Rongve A, Aarsland D, Svendsboe E, Andersen JR. The association between specific
233 neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and
234 carer distress. *Int J Geriatr Psychiatry* **34**, 1421-1428 (2019).
- 235 12 Yuen K, R.-R. N., Verhoeff NPLG, Kumar S, Gallagher D, Flint AJ, Herrmann N, Pollock BG, Mulsant BH,
236 Rajji TK, Voineskos AN, Fischer CE, Mah L; PACt-MD Study Group. Association between Sleep
237 Disturbances and Medial Temporal Lobe Volume in Older Adults with Mild Cognitive Impairment Free
238 of Lifetime History of Depression. *J Alzheimers Dis* **69**, 413-421 (2019).
- 239 13 Boutin, A. *et al.* Transient synchronization of hippocampo-striato-thalamo-cortical networks during
240 sleep spindle oscillations induces motor memory consolidation. *Neuroimage* **169**, 419-430,
241 doi:10.1016/j.neuroimage.2017.12.066 (2018).
- 242 14 Girardeau, G., Inema, I. & Buzsaki, G. Reactivations of emotional memory in the
243 hippocampus-amygdala system during sleep. *Nat Neurosci* **20**, 1634-1642, doi:10.1038/nn.4637
244 (2017).
- 245 15 Alger, S. E., Chambers, A. M., Cunningham, T. & Payne, J. D. The role of sleep in human declarative
246 memory consolidation. *Curr Top Behav Neurosci* **25**, 269-306, doi:10.1007/7854_2014_341 (2015).
- 247 16 Sexton, C. E., Storsve, A. B., Walhovd, K. B., Johansen-Berg, H. & Fjell, A. M. Poor sleep quality is
248 associated with increased cortical atrophy in community-dwelling adults. *Neurology* **83**, 967-973,
249 doi:10.1212/WNL.0000000000000774 (2014).
- 250 17 Branger, P. *et al.* Relationships between sleep quality and brain volume, metabolism, and amyloid
251 deposition in late adulthood. *Neurobiol Aging* **41**, 107-114, doi:10.1016/j.neurobiolaging.2016.02.009
252 (2016).
- 253 18 Sanchez-Espinosa MP, A. M., Cantero JL. Sleep deficits in mild cognitive impairment are related to
254 increased levels of plasma amyloid- β and cortical thinning. *Neuroimage* **98**, 395-404 (2014).
- 255 19 H.A. Keage, S. B., K.L. Yang, K. Morgan, C. Brayne, F.E. Matthews. What sleep characteristics predict
256 cognitive decline in the elderly? *Sleep Med* **13**, 886-892 (2012).
- 257 20 Jelacic M, B. H., Ponds RW, Van Boxtel MP, Houx PJ, Jolles J. Subjective sleep problems in later life as
258 predictors of cognitive decline. Report from the Maastricht Ageing Study (MAAS). *Int J Geriatr*
259 *Psychiatry* **17**, 73-77 (2002).

260